# A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects

> **NCT01762995** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 24 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** Dolutegravir 50 mg
- **DRUG:** Calcium Carbonate 1200 mg
- **DRUG:** Ferrous Fumarate 324 mg

## Key facts

- **NCT ID:** NCT01762995
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01762995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01762995, "A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01762995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*